South Texas Clinical Trials

Texas Oncology in South Texas is no longer allowing visitors to accompany patients. View the full policy here.

Texas Oncology cancer centers in South Texas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the South Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the South Texas area are involved in several types of clinical trials:

Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the South Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the South Texas area and talk to you doctor to determine which clinical trial is right for you.

Anal Cancer

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Biliary Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: III

Bladder Cancer

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: II

Bone Mets

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Weslaco

Phase: I/II

Brain Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Breast Cancer

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Description: A Randomized Double-Blind Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo(NSABP B-59/GBG 96-GeparDouze).

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph2 rib+non-sterAIs HR+HER2- BC (AMELEE) View

Description: A phase II multicenter randomized open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph2 rib+non-sterAIs HR+HER2- BC (AMELEE) View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph2 rib+non-sterAIs HR+HER2- BC (AMELEE) View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph2 rib+non-sterAIs HR+HER2- BC (AMELEE) View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Carcinoid

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-Weslaco

Phase: III

Cervical Cancer

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Colon Cancer

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Description: A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2) (2019-013-GLOB1)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Endometrial Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Esophageal Cancer

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Essential Thrombocythemia

Title: STAR PH3 Pacritinib vs MD choice in MF View

Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-Weslaco

Phase: III

Fallopian Tube Cancer

Title: Ph3 Mirv Sora Epi Ova FTC View

Description: SORAYA: A Phase 3 Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0417)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Gall Bladder Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Gastric Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Head and Neck Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph3 GC4419 Oral Mucositis H&N View

Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: III

Hematologic

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-McAllen

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Weslaco

Kaposi's Sarcoma

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Kidney Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Leukemia

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II

Liver Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Lung Cancer

Title: STAR KEAP1/NRF2 NSCLC View

Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Lymphomas

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: III

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: III

Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Malignant Adenoma

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Weslaco

Phase: I/II

Myelofibrosis

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-Weslaco

Phase: III

Ovarian Cancer

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: III

Pancreatic Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Penile Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Peritoneal Cancer

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Prostate Cancer

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Rectal Cancer

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Renal Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Sarcoma

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Skin Cancer

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: I

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Testicular Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Thyroid Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Urothelial Cancer

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Description: QBGJ398-302: Phase 3 Multicenter Double-Blind Randomized Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Uterine Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Vaginal Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Vulvar Cancer

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Texas Oncology-Harlingen

Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Texas Oncology-McAllen

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-McAllen

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: III

Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: STAR Ph3 FGFR erdafitinib urothelial View

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR BV in pts w/1L cHL or PTCL View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph2 rib+non-sterAIs HR+HER2- BC (AMELEE) View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: STAR Ph3 FGFR erdafitinib urothelial View

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR BV in pts w/1L cHL or PTCL View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph2 rib+non-sterAIs HR+HER2- BC (AMELEE) View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-McAllen

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: II

Texas Oncology-Weslaco

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Weslaco

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: III

Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2 Pemigatinib Solids FGFR View

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph2 rib+non-sterAIs HR+HER2- BC (AMELEE) View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR BV in pts w/1L cHL or PTCL View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR PH3 Nirap Abira HRR mCSPC View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Anal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Indication: Carcinoid

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Title: STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View

Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph3 Fruq + Placebo CC (FRESCO-2) View

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Mirv Sora Epi Ova FTC View

Indication: Peritoneal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Essential Thrombocythemia

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR PH3 Pacritinib vs MD choice in MF View

Indication: Myelofibrosis

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2 Pemigatinib Solids FGFR View

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2 Erdafitinib FGFR Solid Tumors View

Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: II

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: TTFlds cncmnt w/ PTX recurrent ovn cnr View

Description: ENGOT-ov50 / INNOVATE-3: Pivotal Randomized Open-Label Study ofTumor Treating Fields (TTFields 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph2 rib+non-sterAIs HR+HER2- BC (AMELEE) View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph 3 Chemo+Atez/Placbo TNBC View

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View

Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph3 Nirap+Abirat+Pred mCRPC View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR BV in pts w/1L cHL or PTCL View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR Ph2 A+AVD +G-CSF or AOAD in CHL View

Description: SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

No Phase

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-McAllen

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Weslaco

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Title: EAP BGB-3111 B-Cell Malig View

Description: A Single-Arm Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR Ph1 CX-4945 Basal Cell Carcinoma View

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: I

Phase I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR PH 2 ASG-22CE Urothelial Cancer View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Anal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Bone Mets

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Brain Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Uterine Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vaginal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Vulvar Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Testicular Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Malignant Adenoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Penile Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gastric Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kaposi's Sarcoma

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Kidney Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 BLU667 thy NSCLC Sol tum View

Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Phase II

Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 Ak104 Cervical Cancer View

Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: PH2 Tuca+ Tras HER2+ CC View

Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR KEAP1/NRF2 NSCLC View

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: Zanu in Ibrut/Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with I

Share:

South Texas Clinical Trials

Benefits and Risks of Participating in Clinical Trials

Clinical Trial Eligibility